Masaharu Ito

UMN Pharma, Inc. engages in the development, manufacture, and sale of biopharmaceuticals. It operates through a following business division: Next-generation biopharmaceutical in-house development business and Biopharmaceutical contract manufacturing business. The Next-generation biopharmaceutical in-house development business engages in the research and development of next-generation logical vaccine by integrating next-generation biopharmaceutical drug substance manufacturing technology, adjuvant technology and drug delivery technology. The Biopharmaceutical contract manufacturing business offers study samples, investigational drugs, products, and various evaluation test results. The company was founded by Masahiro Michishita and Shuichi Kanazashi on April 20, 2004 and is headquartered in Akita, Japan.

Part of Eisai Co., Ltd., EA Pharma Co., Ltd. is a specialty pharmaceutical company based in Tokyo, Japan. The Japanese company specializes in digestive diseases such as inflammatory intestinal diseases and focuses on advanced research and development and marketing activities to solve unmet medical needs. EA Pharma Co. provides drug discovery research, development research related to gastrointestinal diseases, and drug discovery base technology research to meet the further medical needs of patients. The company's production department aims to create products that have effective and safety as a drug and ensure the quality of the product. EA Pharma Co. aims to be the largest digestive pharmacy in Japan, which was born in the integration of the digestive business of the Eisai group and the Ajinomoto group's digestive business.